| 3/6/2025 | BKCVHY | Moody's puts Viavi on review
|
| 3/5/2025 | BKCVHY | Fitch puts Viavi on negative watch
|
| 3/5/2025 | BKCVHY | S&P puts Viavi on negative watch
|
| 1/31/2025 | CV | Market Commentary: MicroStrategy preferreds upsized, volatile on debut; AST SpaceMobile recovers; Viavi up
|
| 7/15/2024 | BKCVHY | S&P ends watch on Viavi Solutions
|
| 6/25/2024 | BKCVHY | Moody's confirms Viavi ratings
|
| 3/19/2024 | BKCVHY | S&P places Viavi on watch
|
| 3/7/2024 | BKCVHY | Fitch cuts Viavi, rates loan BB+
|
| 3/7/2024 | BKCVHY | Moody’s reviews Viavi for downgrade
|
| 12/7/2023 | BKCVHY | S&P trims Viavi Solutions
|
| 5/22/2023 | BKCVHY | S&P turns Viavi outlook to negative
|
| 3/2/2023 | CV | New Issue: Viavi to issue $250 million 1.625% convertible notes due 2026
|
| 3/2/2023 | CVLM | Viavi swaps convertibles: 1% notes due 2024 for 1.625% notes due 2026
|
| 9/24/2021 | BKCVDDEMIGPV | Market Commentary: Another $3.56 billion clears junk primary; Viavi at a premium; RBC Bearings in demand
|
| 9/23/2021 | BKCVHY | Fitch gives Viavi, notes BB
|
| 9/23/2021 | BKCVHY | Moody's rates Viavi, notes Ba2
|
| 9/23/2021 | BKCVHY | S&P gives Viavi, notes BB+
|
| 10/12/2018 | CVLM | Viavi holders convert $112 million 0.625% convertibles ahead of call
|
| 9/5/2018 | CVLM | Viavi Solutions to redeem $142.74 million 0.625% convertibles Oct. 10
|
| 8/15/2018 | CVLM | Viavi holders put $134.28 million 0.625% convertibles due 2033
|
| 8/13/2018 | CV | Market Commentary: Dycom convertibles drop outright, expand on hedge; Viavi Solutions actively traded
|
| 7/25/2018 | CVLM | Viavi extends put deadline for 0.625% convertibles due 2033
|
| 5/23/2018 | CVLM | Viavi issues $155.5 million 1.75% convertibles in exchange, up 37.5%, $69.5 million for cash
|
| 5/23/2018 | CVLM | Viavi issues $155.5 million 1.75% convertibles in exchange, up 37.5%
|
| 3/22/2017 | CV | Viavi greenshoe exercised, lifts 1% convertibles to $460 million
|
| 3/20/2017 | CV | Market Commentary: Tesla’s new issue remains in focus; Viavi ticks up; Medicines rebounds from Friday lows
|
| 3/20/2017 | CV | Market Commentary: Morning Commentary: Tesla’s new issue remains in focus; Viavi ticks up; Medicines rebounds
|
| 3/6/2017 | CV | Market Commentary: Convertibles flat to lower as broader markets sink; Lumentum slips; Pacira launches deal
|
| 3/6/2017 | CV | Market Commentary: Morning Commentary: Convertibles heavy as broader markets sink; Lumentum slips after strong debut
|
| 3/2/2017 | CV | Market Commentary: Lumentum deal added to convertibles calendar; Viavi fades; PTC drops on clinical trial news
|
| 3/1/2017 | CV | Market Commentary: Square deal comes upsized, jumps over par; Silicon prices; Viavi still busy; Ashford on tap
|
| 3/1/2017 | CV | Market Commentary: Morning Commentary: Square deal comes upsized, jumps over par; Silicon prices; Viavi still busy
|
| 2/28/2017 | CV | Market Commentary: Viavi’s new deal does well on the break; Encore issue lackluster; HCI upsized; calendar eyed
|
| 2/28/2017 | CV | New Issue: Viavi prices $400 million 1% seven-year convertible notes, up 32.5%
|
| 2/27/2017 | CV | Market Commentary: New deals from Encore, Viavi, Silicon Labs and Square on tap; Tesla stock downgraded
|
| 2/27/2017 | CV | Market Commentary: Morning Commentary: Encore Capital, Viavi plan new issues; Tesla stock downgraded, bonds lower
|
| 2/27/2017 | CV | Viavi to price $400 million seven-year convertible notes to yield 0.5%-1%, up 32.5%-37.5%
|
| 8/18/2015 | CV | Viavi adjusts conversion rate on 0.625% debentures after spinoff
|
